For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
PNC-27 is a 32-residue chimeric peptide combining a domain from the tumor suppressor protein p53 with a membrane-penetrating sequence. It kills a wide range of cancer cell types in vitro and in mouse models by binding to HDM-2 (human double minute-2) protein expressed on cancer cell membranes, forming transmembrane pores that lyse the cell. Normal cells, which express little or no membrane-bound HDM-2, are largely spared. Despite 20-plus years of laboratory research, no human clinical trial has been conducted, and a separate commercial operation selling PNC-27 as a cancer cure was publicly warned against by the FDA in 2017 for bacterial contamination.
The complete PNC-27 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use